Risk Factors for the Incidence of Overdose of Etoricoxib Drug in Outpatient at Hospital in Indonesia
Article Sidebar
Main Article Content
Abstract
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) commonly prescribed for the treatment of various inflammatory conditions. However, the risk of overdose associated with the use of etoricoxib in outpatient polyclinic settings remains a significant concern. This study aimed to investigate the potential risk factors contributing to the incidence of etoricoxib overdose in outpatient polyclinic patients. A retrospective observational study was conducted, analyzing data from medical records of patients who had experienced etoricoxib overdose in outpatient polyclinics. The study population included patients who had been prescribed etoricoxib and presented with signs of overdose. The analysis revealed several potential risk factors contributing to the incidence of etoricoxib overdose in outpatient polyclinic patients. Factors such as age, multiphatology and polypharmacy were found to be associated with an increased risk of overdose (P value = 0,001). Additionally, the study highlighted the importance of pharmacist intervention to reducing the risk of etoricoxib overdose in this clinical setting.
Article Details
References
[2] Balazcs, E., et al., A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskeletal Disorders, 2016. 17: p. 1-12.
[3] Tang, H.-y., et al., Efficacy of etoricoxib for ankylosing spondylitis: A protocol for systematic review of randomized controlled trial. Medicine, 2019. 98(15): p. e15155.
[4] Service, N.P.I.S.a.F.Y.R.N.P.I., National Poisons Information Service and Five Year Review National Poisons Information Service. 2009.
[5] Bronstein, A.C., et al., 2009 annual report of the American Association of Poison Control Centers' national poison data system (NPDS): 27th annual report. Clinical Toxicology, 2010. 48(10): p. 979-1178.
[6] AL‐Musawe, L., et al., Polypharmacy, potentially serious clinically relevant drug‐drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life. Pharmacology research & perspectives, 2020. 8(4): p. e00621.
[7] Franco-de la Torre, L., et al., Analgesic efficacy of etoricoxib following third molar surgery: A meta‐analysis. Behavioural Neurology, 2021. 2021(1): p. 9536054.
[8] Rosano, T.G., Ellenhorn’s Medical Toxicology: Diagnosis and Treatment of Human Poisoning, Matthew J. Ellenhorn, Seth Schonwald, Gary Ordog, and Jonathan Wasserberger. Baltimore, MD: Williams and Wilkins, 1997, 2047 pp., $199, ISBN 0–683-30031–8. 1998, Oxford University Press.
[9] Heim, H.-K. and K. Broich, Selective COX-2 inhibitors and risk of thromboembolic events–regulatory aspects. Thrombosis and haemostasis, 2006. 96(10): p. 423-432.
[10] Hillis, W.S., Areas of emerging interest in analgesia: cardiovascular complications. American journal of therapeutics, 2002. 9(3): p. 259-269.
[11] Baron, J.A., et al., Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. The Lancet, 2008. 372(9651): p. 1756-1764.
[12] Kirkby, N.S., et al., Cyclooxygenase-2 selectively controls renal blood flow through a novel PPARβ/δ-dependent vasodilator pathway. Hypertension, 2018. 71(2): p. 297-305.
[13] Recinella, G., et al., Probable Etoricoxib-Induced severe thrombocytopenia: a case report. Medical Principles and Practice, 2019. 28(4): p. 387-389.
[14] Rabie, A.S.I., et al. Clinical consequences for individuals treated with tocilizumab for serious COVID-19 Infection. in Healthcare. 2023. MDPI.
[15] Walker, C., Are all oral COX‐2 selective inhibitors the same? A consideration of celecoxib, etoricoxib, and diclofenac. International journal of rheumatology, 2018. 2018(1): p. 1302835.
[16] Kwiatkowska, B., et al., Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia/Rheumatology, 2017. 55(6): p. 290-297.
[17] Hailu, B.Y., et al., Drug related problems in admitted geriatric patients: the impact of clinical pharmacist interventions. BMC geriatrics, 2020. 20: p. 1-8.
[18] Albayrak, A., et al., Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital. BMC Health Services Research, 2022. 22(1): p. 79.
[19] Osoro, I., et al., Pharmacist interventions in minimizing drug related problems in diabetes with co-existing hypertension: a five-year overview and ground report from India. International Journal of Public Health, 2023. 68: p. 1605808.
[20] Shahrami, B., et al., Identification of drug‐related problems followed by clinical pharmacist interventions in an outpatient pharmacotherapy clinic. Journal of Clinical Pharmacy and Therapeutics, 2022. 47(7): p. 964-972.
[21] Wang, X., et al., Impact of pharmacist‐led medication therapy management in ambulatory elderly patients with chronic diseases. British journal of clinical pharmacology, 2021. 87(7): p. 2937-2944.